Societal value of stem cell therapy in stroke--a modeling study

Cerebrovascular Diseases
Johanna SvenssonZaal Kokaia

Abstract

Stroke is one of the major causes of disability in the adult population and represents a heavy social and economic burden. Currently available therapeutic tools to support the recovery of impaired brain functions are quite limited. Animal studies have demonstrated that neuronal replacement and partial reconstruction of neural circuitry or modulation of the recovery process is possible with cell transplantation in the damaged adult brain. Stem cell therapy (SCT) may promote functional recovery also in stroke patients, thereby improving quality of life and reducing costs. Our aim was to estimate the potential societal value of SCT in stroke patients. We created a decision-analytic model in Microsoft Excel 2010 to assess life-long costs and quality-adjusted life years (QALYs) of SCT versus standard care for stroke patients from a societal perspective. The model structure consisted of 7 health states in accordance with the modified Rankin Scale (mRS). We modeled for age (55, 65, and 75 years), functional status at discharge (mRS 2, 3, and 4), effectiveness of SCT (50 and 25% increase in the probability to improve 1 mRS grade), mode of stem cell administration, risk of recurrent stroke, complications of intervention, and use of immu...Continue Reading

References

Feb 15, 2001·Neuroepidemiology·S M Lai, P W Duncan
Feb 28, 2002·Cerebrovascular Diseases·Jean-François SpielerPierre Amarenco
Feb 7, 2004·Stroke; a Journal of Cerebral Circulation·Kate HardieCraig Anderson
Sep 28, 2004·International Journal of Technology Assessment in Health Care·Ola GhatnekarAndreas Terént
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Olle Lindvall, Anders Björklund
Jun 2, 2005·Annals of Neurology·Oh Young BangGwang Lee
Aug 27, 2005·Journal of Neurosurgery·Douglas KondziolkaJeffrey Teraoka
Oct 26, 2005·Brain : a Journal of Neurology·Paola PicciniOlle Lindvall
Sep 6, 2007·Health Economics·Bengt LiljasNils-Olov Stålhammar
Jan 31, 2008·BMJ : British Medical Journal·Karsten Bruins SlotUNKNOWN Lothian Stroke Register
Sep 27, 2008·Stroke; a Journal of Cerebral Circulation·S Claiborne Johnston
May 30, 2009·Annals of Neurology·Randolph S MarshallJohn W Krakauer
Oct 28, 2009·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Oliver Rivero-AriasRamon Luengo-Fernandez
Nov 7, 2009·Cerebrovascular Diseases·Bruce Ovbiagele, Jeffrey L Saver
Nov 11, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Stephanie R EarnshawAshish V Joshi
Jan 29, 2011·Stroke; a Journal of Cerebral Circulation·Sean I SavitzUNKNOWN STEPS Participants
Jul 16, 2011·Stroke; a Journal of Cerebral Circulation·Olle Lindvall, Zaal Kokaia

❮ Previous
Next ❯

Citations

Dec 3, 2014·Revue neurologique·O DetanteC Remy
Nov 19, 2017·Translational Stroke Research·Olivier DetanteJukka Jolkkonen
Apr 5, 2017·International Journal of Stroke : Official Journal of the International Stroke Society·Katarina Steen CarlssonBo Norrving
Mar 11, 2020·British Journal of Clinical Pharmacology·Huw Lloyd-Williams, Dyfrig A Hughes

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Acute Stroke

A stroke occurs when blood supply to the brain is interrupted depriving the brain of oxygen and nutrients. This feed focuses cerebrovascular accidents including ischemic and paralytic stroke.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.